Abstract
Background: Insulin resistance is a pathological condition characterized by the failure of target cells to uptake and metabolize glucose in response to insulin. In particular, the elevated concentrations of glucose, insulin and free insulin growth factor-1, which result from insulin resistance, may generate a pro-inflammatory and protumorigenic state. These alterations may underlie the increased risk to develop various types of cancer as well as the worse cancer prognosis observed in obese and diabetic patients. MicroRNAs are short molecules of noncoding endogenous RNA, which are involved in several physio-pathological conditions like glucose homeostasis, lipid metabolism, insulin signaling and resistance. MicroRNAs play also a crucial role in tumorigenesis, acting as oncomirs or tumor suppressors depending on the cell context.
Methods: Here, we recapitulate the role of certain microRNAs that are associated with both insulin resistance and cancer, and discuss their potential to be considered as therapeutic targets.
Results: Several studies have highlighted the action of diverse microRNAs in the aforementioned disorders. For instance, three microRNA clusters namely miR-103/107, miR-221/222 and miR-29 have been found to be upregulated in insulin resistance and certain types of cancer. These microRNAs have been shown to target genes like PTEN, Dicer and caveolins that are largely involved in important processes relevant to both insulin resistance and cancer.
Conclusion: Certain microRNAs may represent potential drug targets common to both insulin resistance and cancer. In particular, the inhibition of miR-103/107, miR-221/222 and miR-29 may be taken into account in novel pharmacological approaches aiming to treat these two disorders.
Keywords: Insulin resistance, cancer, miRNAs, miR-103/107; miR-221/222, miR-29.
Current Pharmaceutical Design
Title:Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer
Volume: 23 Issue: 25
Author(s): Adele Vivacqua*, Paola De Marco, Antonino Belfiore and Marcello Maggiolini*
Affiliation:
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, CS,Italy
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, CS,Italy
Keywords: Insulin resistance, cancer, miRNAs, miR-103/107; miR-221/222, miR-29.
Abstract: Background: Insulin resistance is a pathological condition characterized by the failure of target cells to uptake and metabolize glucose in response to insulin. In particular, the elevated concentrations of glucose, insulin and free insulin growth factor-1, which result from insulin resistance, may generate a pro-inflammatory and protumorigenic state. These alterations may underlie the increased risk to develop various types of cancer as well as the worse cancer prognosis observed in obese and diabetic patients. MicroRNAs are short molecules of noncoding endogenous RNA, which are involved in several physio-pathological conditions like glucose homeostasis, lipid metabolism, insulin signaling and resistance. MicroRNAs play also a crucial role in tumorigenesis, acting as oncomirs or tumor suppressors depending on the cell context.
Methods: Here, we recapitulate the role of certain microRNAs that are associated with both insulin resistance and cancer, and discuss their potential to be considered as therapeutic targets.
Results: Several studies have highlighted the action of diverse microRNAs in the aforementioned disorders. For instance, three microRNA clusters namely miR-103/107, miR-221/222 and miR-29 have been found to be upregulated in insulin resistance and certain types of cancer. These microRNAs have been shown to target genes like PTEN, Dicer and caveolins that are largely involved in important processes relevant to both insulin resistance and cancer.
Conclusion: Certain microRNAs may represent potential drug targets common to both insulin resistance and cancer. In particular, the inhibition of miR-103/107, miR-221/222 and miR-29 may be taken into account in novel pharmacological approaches aiming to treat these two disorders.
Export Options
About this article
Cite this article as:
Vivacqua Adele*, Marco De Paola , Belfiore Antonino and Maggiolini Marcello *, Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer, Current Pharmaceutical Design 2017; 23 (25) . https://dx.doi.org/10.2174/1381612823666170622105123
DOI https://dx.doi.org/10.2174/1381612823666170622105123 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bronchoscopic Appearance of Tracheal Adenoid Cystic Carcinoma
Current Respiratory Medicine Reviews Preventive Role of Resveratrol Against Inflammatory Cytokines and Related Diseases
Current Pharmaceutical Design Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials
Current Hypertension Reviews Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Editorial [Hot Topic: Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This (Executive Guest Editors: Aldo Pende and Fabrizio Montecucco )]
Current Pharmaceutical Design Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Preeclampsia: Placental Origins, New Predictors and New Therapeutic Strategies
Current Women`s Health Reviews Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Preventing Death from Abdominal Aortic Aneurysm Rupture
Vascular Disease Prevention (Discontinued) VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients
Current Vascular Pharmacology The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Current Vascular Pharmacology Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews